Author(s)

Inmaculada Rapado, Juan José Lahuerta, Laura Montejano, María Ángeles Montalbán, Laura Pares, Joaquín Martínez- López

Servicio de Bioquímica, Hospital Universitario 12 de Octubre, Madrid, Spain.
Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, Spain;.

A 64-year-old woman with IgA kappa multiple myeloma was treated with thalidomide-dexa- methasone. Due to progression of the disease, bortezomib, doxorubicin and dexamethasone were administered, followed by autologous stem cell transplantation. Although near-complete remission was achieved, 5 months later, neuro- logical symptoms appeared and the patient was diagnosed with multiple myeloma with cells in- filtrating the spinal cord. Bis-chloronitrosourea, bortezomib and lenalidomide were then admin- istered and although the patient remained neu- rologically asymptomatic, she died 3 months later becausee of disease progression. Lena- lidomide entered into the cerebrospinal fluid (confirmed by ultrasensitive high-performance liquid chromatography), although did not im- prove the poor prognosis of multiple myeloma involving the central nervous system.

Lenalidomide; Multiple Myeloma; Spinal Cord Infiltration; High-Performance Liquid Chromatography

Rapado, I., Lahuerta, J., Montejano, L., Montalbán, M., Pares, L. and López, J. (2012) New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography. Modern Chemotherapy, 1, 11-13. doi: 10.4236/mc.2012.12003.